

Quest has the solutions you need to diagnose multiple myeloma

Quest offers a complete diagnostic solution for multiple myeloma

When it comes to multiple myeloma, earlier detection means better outcomes. Quest multiple myeloma testing supports your patients through every stage of the journey—from detection to diagnosis to post treatment monitoring.

We offer the **Myeloma Detection Panel**, **Basic** to detect multiple myeloma and smoldering myeloma with 100% sensitivity, and the **Myeloma Detection Panel**, **Comprehensive** to ensure a full picture of a patient diagnosis.

If the cause is unclear, it could be multiple myeloma

Patients with multiple myeloma are difficult to diagnose because they often present with diverse and nonspecific symptoms such as:

• Back pain • Bone pain • Fatigue

If you have patients with these symptoms but are getting indeterminate test results, you might consider testing for multiple myeloma.



African American males and females are twice as likely to be diagnosed with multiple myeloma¹

Males	
African American	17.0
All races	9.0
Females	
African American	13.1
All races 6.0	

Rate of new cases per 100,000 persons by race/ethnicity & sex: myeloma


Proper testing equals accurate results

Test Name	Test Code
Myeloma Detection Panel, Basic (sPE + sIFE + sFLC)ª	38479
Myeloma Detection Panel, Comprehensive (Basic + uIFE + uPE) ^b	38480
 a. Individual components can be ordered separately: serum protein electrophoresis-747; serum immunofixa 	tion-549:

a. Individual components can be ordered separately: serum protein electrophoresis-747; serum immunofixation-549 quantitative serum $\kappa \lambda$ chain, with ratio-11234.

 b. Individual components can be ordered separately: serum protein electrophoresis-747; serum immunofixation-549; quantitative serum κ/λ chain, with ratio-11234; Protein Electrophoresis, 24-Hour Urine-750; Immunofixation (uIFE), Urine-213.

These panels follow IMWG guidelines.



To learn more about multiple myeloma panels, talk to your sales representative or the Advanced Diagnostics Oncology Client Services team at 1.833.773.1441

References:

1. SEER*Explorer. National Cancer Institute Surveillance Epidemiology and End Results Program. Updated 2018.

Accessed June 10, 2021.https://seer.cancer.gov/explorer/application.html?site=89.

Test codes may vary by location. Please contact your local laboratory for more information.

Image content features a model and is intended for illustrative purposes only.

QuestDiagnostics.com

Quest, Quest Diagnostics, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—[®] and TM—are the property of their respective owners. © 2021 Quest Diagnostics Incorporated. All rights reserved. SB10354 6/2021